{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T14:31:14Z","timestamp":1770906674785,"version":"3.50.1"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T00:00:00Z","timestamp":1761004800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T00:00:00Z","timestamp":1761004800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["82471964"],"award-info":[{"award-number":["82471964"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program of China","doi-asserted-by":"publisher","award":["2024YFC3405303"],"award-info":[{"award-number":["2024YFC3405303"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Med Imaging"],"DOI":"10.1186\/s12880-025-01968-8","type":"journal-article","created":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T10:27:41Z","timestamp":1761042461000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["The feasibility of the radiomics models for tumor-infiltrating lymphocytes level prediction in breast cancer based on dynamic contrast-enhanced MRI"],"prefix":"10.1186","volume":"25","author":[{"given":"Yuan","family":"Peng","sequence":"first","affiliation":[]},{"given":"Xuege","family":"Hu","sequence":"additional","affiliation":[]},{"given":"Yulu","family":"Liu","sequence":"additional","affiliation":[]},{"given":"Dingbao","family":"Chen","sequence":"additional","affiliation":[]},{"given":"Xiufeng","family":"Chen","sequence":"additional","affiliation":[]},{"given":"Yi","family":"Wang","sequence":"additional","affiliation":[]},{"given":"Shu","family":"Wang","sequence":"additional","affiliation":[]}],"member":"297","published-online":{"date-parts":[[2025,10,21]]},"reference":[{"issue":"1","key":"1968_CR1","first-page":"17","volume":"73","author":"RL Siegel","year":"2023","unstructured":"Siegel RL, Miller KD, Wagle NS, Jemal A. Cancer statistics, 2023. CA Cancer J Clin. 2023;73(1):17\u201348.","journal-title":"CA Cancer J Clin"},{"issue":"2","key":"1968_CR2","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1016\/j.bbcan.2017.10.003","volume":"1868","author":"D De Melo Gagliato","year":"2017","unstructured":"De Melo Gagliato D, Cortes J, Curigliano G, Loi S, Denkert C, Perez-Garcia J, et al. Tumor-infiltrating lymphocytes in breast cancer and implications for clinical practice. Biochim Biophys Acta Rev Cancer. 2017;1868(2):527\u201337.","journal-title":"Biochim Biophys Acta Rev Cancer"},{"key":"1968_CR3","doi-asserted-by":"publisher","first-page":"108773","DOI":"10.1016\/j.ejrad.2019.108773","volume":"123","author":"W Murakami","year":"2020","unstructured":"Murakami W, Tozaki M, Sasaki M, Hida AI, Ohi Y, Kubota K, et al. Correlation between (18)F-FDG uptake on PET\/MRI and the level of tumor-infiltrating lymphocytes (TILs) in triple-negative and HER2-positive breast cancer. Eur J Radiol. 2020;123:108773.","journal-title":"Eur J Radiol"},{"issue":"28","key":"1968_CR4","doi-asserted-by":"publisher","first-page":"44288","DOI":"10.18632\/oncotarget.9988","volume":"7","author":"K Wand","year":"2016","unstructured":"Wand K, Xu J, Zhang T, Xue D. Tumor-infiltrating lymphocytes in breast cancer predict the response to chemotherapy and survival outcome: A meta-analysis. Oncotarget. 2016;7(28):44288\u201398.","journal-title":"Oncotarget"},{"issue":"12","key":"1968_CR5","doi-asserted-by":"publisher","first-page":"e115103","DOI":"10.1371\/journal.pone.0115103","volume":"9","author":"Y Mao","year":"2014","unstructured":"Mao Y, Qu Q, Zhang YZ, Liu JJ, Chen XS, Shen KW. The value of tumor infiltrating lymphocytes (TILs) for predicting response to neoadjuvant chemotherapy in breast cancer: a systematic review and meta-analysis. PLoS ONE. 2014;9(12):e115103.","journal-title":"PLoS ONE"},{"issue":"1","key":"1968_CR6","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/S1470-2045(17)30904-X","volume":"19","author":"C Denkert","year":"2018","unstructured":"Denkert C, Von Minckwitz G, Darb-Esfahani S, Lederer B, I Heppner B, Weber E. Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy. Lancet Oncol. 2018;19(1):40\u201350.","journal-title":"Lancet Oncol"},{"issue":"1","key":"1968_CR7","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1186\/s13058-020-01283-w","volume":"22","author":"C Kolberg-Liedtke","year":"2020","unstructured":"Kolberg-Liedtke C, Gluz O, Heinisch F, Feuerhake F, Kreipe H, Clemens M, et al. Association of TILs with clinical parameters, recurrence Score\u00ae results, and prognosis in patients with early HER2-negative breast cancer (BC)-a translational analysis of the prospective WSG PlanB trial. Breast Cancer Res. 2020;22(1):47.","journal-title":"Breast Cancer Res"},{"issue":"8","key":"1968_CR8","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1093\/jnci\/djab004","volume":"113","author":"LA Emens","year":"2021","unstructured":"Emens LA, Molinero L, Loi S, Ruge HS, Schneeweiss A, Dieras Veronique, et al. Atezolizumab and nab-Paclitaxel in advanced Triple-Negative breast cancer: biomarker evaluation of the IMpassion130 study. J Natl Cancer Inst. 2021;113(8):1005\u201316.","journal-title":"J Natl Cancer Inst"},{"issue":"4","key":"1968_CR9","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1016\/S1470-2045(20)30754-3","volume":"22","author":"EP Winer","year":"2021","unstructured":"Winer EP, Lipatov O, Im SA, Goncalves A, Munoz-Couselo E, Lee KS, et al. Pembrolizumab versus investigator-choice chemotherapy for metastatic triple-negative breast cancer (KEYNOTE-119): a randomised, open-label, phase 3 trial. Lancet Oncol. 2021;22(4):499\u2013511.","journal-title":"Lancet Oncol"},{"issue":"3","key":"1968_CR10","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1093\/annonc\/mdy518","volume":"30","author":"S Adams","year":"2019","unstructured":"Adams S, Loi S, Toppmeyer D, Cescon DW, Laurentiis MD, Nanda R, et al. Pembrolizumab monotherapy for previously untreated, PD-L1-positive, metastatic triple-negative breast cancer: cohort B of the phase II KEYNOTE-086 study. Ann Oncol. 2019;30(3):405\u201311.","journal-title":"Ann Oncol"},{"issue":"2","key":"1968_CR11","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1093\/annonc\/mdu450","volume":"26","author":"R Salgado","year":"2015","unstructured":"Salgado R, Denkert C, Demaria S, Sirtaine N, Klauschen F, Pruneri G, et al. The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an international TILs working group 2014. Ann Oncol. 2015;26(2):259\u201371.","journal-title":"Ann Oncol"},{"issue":"5","key":"1968_CR12","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1097\/PAP.0000000000000162","volume":"24","author":"S Hendry","year":"2017","unstructured":"Hendry S, Salgado R, Gevaert T, Russell P, John J, Thapa B, et al. Assessing tumor-infiltrating lymphocytes in solid tumors: A practical review for pathologists and proposal for a standardized method from the international immunooncology biomarkers working group: part 1: assessing the host immune Response, TILs in invasive breast carcinoma and ductal carcinoma in Situ, metastatic tumor deposits and areas for further research. Adv Anat Pathol. 2017;24(5):235\u201351.","journal-title":"Adv Anat Pathol"},{"issue":"7","key":"1968_CR13","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1016\/j.crad.2010.04.005","volume":"65","author":"RJ Gillies","year":"2010","unstructured":"Gillies RJ, Anderson AR, Gatenby RA, Morse DL. The biology underlying molecular imaging in oncology: from genome to anatome and back again. Clin Radiol. 2010;65(7):517\u201321.","journal-title":"Clin Radiol"},{"issue":"4","key":"1968_CR14","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1016\/j.ejca.2011.11.036","volume":"48","author":"P Lambin","year":"2012","unstructured":"Lambin P, Rios-Velazquez E, Leijienaar R, Carvalho S, Van Stiphout R G P M, Granton P, et al. Radiomics: extracting more information from medical images using advanced feature analysis. Eur J Cancer. 2012;48(4):441\u20136.","journal-title":"Eur J Cancer"},{"issue":"4","key":"1968_CR15","first-page":"044502","volume":"7","author":"QY Hu","year":"2020","unstructured":"Hu QY, Whitney HM, Giger ML. Radiomics methodology for breast cancer diagnosis using multiparametric magnetic resonance imaging. J Med Imaging (Bellingham). 2020;7(4):044502.","journal-title":"J Med Imaging (Bellingham)"},{"issue":"2","key":"1968_CR16","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1002\/jmri.27098","volume":"52","author":"Q Zhang","year":"2020","unstructured":"Zhang Q, Peng YS, Liu W, Bai JY, Zheng J, Yang XD, et al. Radiomics based on multimodal MRI for the differential diagnosis of benign and malignant breast lesions. J Magn Reson Imaging. 2020;52(2):596\u2013607.","journal-title":"J Magn Reson Imaging"},{"issue":"4","key":"1968_CR17","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1038\/s41416-018-0185-8","volume":"119","author":"A Saha","year":"2018","unstructured":"Saha A, Harowicz MR, Grimm LJ, Kim CE, Ghate SV, Walsh R, et al. A machine learning approach to radiogenomics of breast cancer: a study of 922 subjects and 529 DCE-MRI features. Br J Cancer. 2018;119(4):508\u201316.","journal-title":"Br J Cancer"},{"issue":"12","key":"1968_CR18","doi-asserted-by":"publisher","first-page":"3538","DOI":"10.1158\/1078-0432.CCR-18-3190","volume":"25","author":"ZY Liu","year":"2019","unstructured":"Liu ZY, Li ZL, Qu JR, Zhang RZ, Zhou XZ, Li LF, et al. Radiomics of multiparametric MRI for pretreatment prediction of pathologic complete response to neoadjuvant chemotherapy in breast cancer: A multicenter study. Clin Cancer Res. 2019;25(12):3538\u201347.","journal-title":"Clin Cancer Res"},{"issue":"2","key":"1968_CR19","doi-asserted-by":"publisher","first-page":"e44","DOI":"10.1016\/j.acra.2020.02.006","volume":"28","author":"WX Liu","year":"2021","unstructured":"Liu WX, Cheng YL, Liu ZY, Liu CL, Cattell R, Xie XY, et al. Preoperative prediction of Ki-67 status in breast cancer with multiparametric MRI using transfer learning. Acad Radiol. 2021;28(2):e44\u201353.","journal-title":"Acad Radiol"},{"issue":"12","key":"1968_CR20","doi-asserted-by":"publisher","first-page":"e2028086","DOI":"10.1001\/jamanetworkopen.2020.28086","volume":"3","author":"YF Yu","year":"2020","unstructured":"Yu YF, Tan YJ, Xie CM, Hu QG, Ouyang J, Chen YJ, et al. Development and validation of a preoperative magnetic resonance imaging Radiomics-Based signature to predict axillary lymph node metastasis and Disease-Free survival in patients with Early-Stage breast cancer. JAMA Netw Open. 2020;3(12):e2028086.","journal-title":"JAMA Netw Open"},{"issue":"10","key":"1968_CR21","doi-asserted-by":"publisher","first-page":"2086","DOI":"10.1002\/cncr.31272","volume":"124","author":"MJ Kwa","year":"2018","unstructured":"Kwa MJ, Adams S. Checkpoint inhibitors in triple-negative breast cancer (TNBC): where to go from here. Cancer. 2018;124(10):2086\u2013103.","journal-title":"Cancer"},{"issue":"1","key":"1968_CR22","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1038\/s41523-022-00500-3","volume":"8","author":"FO Ademuyiwa","year":"2022","unstructured":"Ademuyiwa FO, Gao F, Street CR, Chen I, Northfelt DW, Wesolowski R, et al. A randomized phase 2 study of neoadjuvant carboplatin and Paclitaxel with or without Atezolizumab in triple negative breast cancer (TNBC) - NCI 10013. NPJ Breast Cancer. 2022;8(1):134.","journal-title":"NPJ Breast Cancer"},{"issue":"5","key":"1968_CR23","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1007\/s12282-019-00958-3","volume":"26","author":"K Fukui","year":"2019","unstructured":"Fukui K, Masumoto N, Shiroma N, Kanou A, Sasada S, Emi A, et al. Novel tumor-infiltrating lymphocytes ultrasonography score based on ultrasonic tissue findings predicts tumor-infiltrating lymphocytes in breast cancer. Breast Cancer. 2019;26(5):573\u201380.","journal-title":"Breast Cancer"},{"key":"1968_CR24","doi-asserted-by":"publisher","first-page":"628577","DOI":"10.3389\/fonc.2021.628577","volume":"11","author":"HW Yu","year":"2021","unstructured":"Yu HW, Meng X, Chen H, Liu J, Gao WW, Du L, et al. Predicting the level of Tumor-Infiltrating lymphocytes in patients with breast cancer: usefulness of mammographic radiomics features. Front Oncol. 2021;11:628577.","journal-title":"Front Oncol"},{"issue":"3","key":"1968_CR25","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1007\/s10549-019-05339-0","volume":"177","author":"SS Sasada","year":"2019","unstructured":"Sasada SS, Shiroma N, Goda N, Kajitani K, Emi A, Masumoto N, et al. The relationship between ring-type dedicated breast PET and immune microenvironment in early breast cancer. Breast Cancer Res Treat. 2019;177(3):651\u20137.","journal-title":"Breast Cancer Res Treat"},{"issue":"1","key":"1968_CR26","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1186\/s13058-018-1039-2","volume":"20","author":"J Wu","year":"2018","unstructured":"Wu J, Li XJ, Teng XD, Rubin DL, Napel S, Daniel BL, et al. Magnetic resonance imaging and molecular features associated with tumor-infiltrating lymphocytes in breast cancer [J]. Breast Cancer Res. 2018;20(1):101.","journal-title":"Breast Cancer Res"},{"issue":"5","key":"1968_CR27","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1016\/j.clbc.2020.12.008","volume":"21","author":"N Xu","year":"2021","unstructured":"Xu N, Zhou JJ, He XX, Ye SX, Miao HW, Liu JR, et al. Radiomics model for evaluating the level of Tumor-Infiltrating lymphocytes in breast cancer based on dynamic Contrast-Enhanced MRI. Clin Breast Cancer. 2021;21(5):440\u2013e91.","journal-title":"Clin Breast Cancer"},{"issue":"3","key":"1968_CR28","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1002\/jmri.27910","volume":"55","author":"TT Bian","year":"2022","unstructured":"Bian TT, Wu ZJ, Lin Q, Mao Y, Wang HB, Chen JJ, et al. Evaluating Tumor-Infiltrating lymphocytes in breast cancer using preoperative MRI-Based radiomics. J Magn Reson Imaging. 2022;55(3):772\u201384.","journal-title":"J Magn Reson Imaging"},{"issue":"2","key":"1968_CR29","doi-asserted-by":"publisher","first-page":"864","DOI":"10.1007\/s00330-021-08173-5","volume":"32","author":"WJ Tang","year":"2022","unstructured":"Tang WJ, Kong QC, Cheng ZX, Liang YS, Jin Z, Chen LX, et al. Performance of radiomics models for tumour-infiltrating lymphocyte (TIL) prediction in breast cancer: the role of the dynamic contrast-enhanced (DCE) MRI phase. Eur Radiol. 2022;32(2):864\u201375.","journal-title":"Eur Radiol"},{"issue":"9","key":"1968_CR30","doi-asserted-by":"publisher","first-page":"1520","DOI":"10.3390\/cancers17091520","volume":"17","author":"DH Jang","year":"2025","unstructured":"Jang DH, Kolios C, Osapoetra LO, Sannachi L, Curpen B, Pejovic-Milic A, et al. Pre-Treatment prediction of breast cancer response to neoadjuvant chemotherapy using intratumoral and peritumoral radiomics from T2-Weighted and Contrast-Enhanced T1-Weighted MRI. Cancers (Basel). 2025;17(9):1520.","journal-title":"Cancers (Basel)"},{"issue":"4","key":"1968_CR31","doi-asserted-by":"publisher","first-page":"e192561","DOI":"10.1001\/jamanetworkopen.2019.2561","volume":"2","author":"N Braman","year":"2019","unstructured":"Braman N, Prasanna P, Whitney J, Singh S, Beig N, Etesami M, et al. Association of peritumoral radiomics with tumor biology and pathologic response to preoperative targeted therapy for HER2 (ERBB2)-Positive breast cancer. JAMA Netw Open. 2019;2(4):e192561.","journal-title":"JAMA Netw Open"},{"key":"1968_CR32","doi-asserted-by":"crossref","unstructured":"Song QK, Shi F, Adair M, Chang H, Guan XD, Zhao YJ et al. Cell Counts, rather than Proportion, of CD8\/PD-1 Tumor-Infiltrating Lymphocytes in a Tumor Microenvironment Associated with Pathological Characteristics of Chinese Invasive Ductal Breast Cancer. J Immunol Res. 2019; 2019: 8505021.","DOI":"10.1155\/2019\/8505021"},{"issue":"3","key":"1968_CR33","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1097\/COC.0b013e3182467d90","volume":"36","author":"ST Kim","year":"2013","unstructured":"Kim ST, Jeong H, Woo OH, Seo JH, Kim A, Lee ES, et al. Tumor-infiltrating lymphocytes, tumor characteristics, and recurrence in patients with early breast cancer. Am J Clin Oncol. 2013;36(3):224\u201331.","journal-title":"Am J Clin Oncol"}],"container-title":["BMC Medical Imaging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12880-025-01968-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12880-025-01968-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12880-025-01968-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T23:03:37Z","timestamp":1761087817000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcmedimaging.biomedcentral.com\/articles\/10.1186\/s12880-025-01968-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,21]]},"references-count":33,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1968"],"URL":"https:\/\/doi.org\/10.1186\/s12880-025-01968-8","relation":{},"ISSN":["1471-2342"],"issn-type":[{"value":"1471-2342","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,21]]},"assertion":[{"value":"26 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was approved by the Institutional Review Board and Ethics Committee of Peking University People\u2019s Hospital and the informed consent to participate was waived by the ethics committee. Committee\u2019s reference in accordance with the Declaration of Helsinki (2024PHB246-001).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not Applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"420"}}